MedTrace Logo

Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of Warfarin

NCT02779348 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-08-24

No results posted yet for this study

Summary

The purpose of this study is to determine whether multiple-dose administration of nebicapone affects the pharmacokinetics of warfarin.

Conditions

  • Healthy

Interventions

DRUG

BIA 3-202

Nebicapone tablets 200 mg

DRUG

warfarin

Varfine® 5 mg (warfarin 5 mg) tablets

Sponsors & Collaborators

  • Bial - Portela C S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • Portugal

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02779348 on ClinicalTrials.gov